论文部分内容阅读
目的本研究探讨培美曲塞单药或联合顺铂治疗晚期复发性非小细胞肺癌的近期疗效及药物不良反应。方法经病理学或细胞学确诊的复发性非小细胞晚期肺癌患者24例。单药治疗培美曲塞;联合治疗培美曲塞联合顺铂;评价近期疗效和不良反应。结果 24例中无完全缓解病例,部分缓解5例,稳定8例,进展11例,近期有效20.83%,临床获益率54.17%。主要不良反应为粒细胞下降、贫血和胃肠反应。结论培美曲塞单药或联合方案治疗晚期复发性非小细胞肺癌疗效确切,不良反应发生率低,耐受性较好。
Objective To investigate the short-term efficacy and side effects of pemetrexed monotherapy or cisplatin in the treatment of advanced recurrent non-small cell lung cancer. Methods Twenty-four patients with recurrent non-small cell lung cancer diagnosed by pathology or cytology were included. Monotherapy pemetrexed; combination therapy pemetrexed combined with cisplatin; evaluation of recent efficacy and adverse reactions. Results There were no complete remission cases in 24 cases, partial remission in 5 cases, stable in 8 cases, progression in 11 cases, and immediate success in 20.83%. The clinical benefit rate was 54.17%. The main adverse reactions were neutropenia, anemia and gastrointestinal reactions. Conclusions Pemetrexed alone or in combination regimen is effective in treating patients with advanced recurrent non-small cell lung cancer with low incidence of adverse reactions and good tolerability.